Flanagan, A.M. and Chambers, T.J. (1991) Inhibition of Bone Resorption by Bisphosphonates Interactions between Bisphosphonates, Osteoclasts, and Bone. Calcified Tissue International, 49, 407-415. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

Flanagan, A.M. and Chambers, T.J. (1991) Inhibition of Bone Resorption by Bisphosphonates: Interactions between Bisphosphonates, Osteoclasts, and Bone. Calcified Tissue International, 49, 407-415. http://dx.doi.org/10.1007/BF02555852

has been cited by the following article:

TITLE: Effect of Bisphosphonate on Osteoclast of Bone

AUTHORS: Sarah Ralte, Asima Bhattacharyya

KEYWORDS: Osteoclast, Bone Resorption, Bisphosphonate, Mechanism of Action

JOURNAL NAME: Forensic Medicine and Anatomy Research, Vol.2 No.3, July 21, 2014

ABSTRACT: Bisphosphonates are synthetic analogues of naturally occurring pyrophosphate molecule and are potent inhibitors of osteoclastic bone resorption. Bisphosphonates bind to hydroxyapatite crystals with high affinity and after incorporation by osteoclasts, the primary target cell, it inhibits osteoclastic bone resorption. The anti-resorptive effect has been shown to occur in organ culture as well as in-vivo, but the precise mechanism by which it exerts its bone resorbing effect is not yet fully understood. In vitro and in vivo studies have demonstrated that zoledronate is a more potent inhibitor of osteoclasts than earlier bisphosphonates. Bisphosphonates have now emerged as a leading therapeutic agent for the treatment of hypercalcaemia of malignancy, bone metabolic diseases, Paget’s disease and postmenopausal osteoporosis.